Physiogenix

Physiogenix provides preclinical in vivo and ex vivo CRO services, with over 15 years of expertise in evaluating drugs targeting metabolic disorders, such as obesity, diabetes, NASH, fibrosis, diabetic nephropathy, cardiovascular complications, etc.